Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rilotumumab · 1 trial · 3 indications
DLTs are defined as grade 3 or higher adverse events that are related to rilotumumab during the first cycle of therapy. This does not include specific toxicities (eg nausea and vomiting) that are common in cancer patients unless specific criteria are met.
DLTs are defined as grade 3 or higher adverse events that are related to rilotumumab or the combination of rilotumumab and CX during the first cycle of therapy. This does not include specific toxicities (eg nausea and vomiting) that are common in cancer patients unless specific criteria are met.
| Arm | Type | Description |
|---|---|---|
| Rilotumumab Monotherapy | EXPERIMENTAL | Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W |
| Rilotumumab plus CX | EXPERIMENTAL | Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W |
| Name | Type | Description |
|---|---|---|
| Rilotumumab | DRUG | Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. |
Key Inclusion Criteria: * Japanese subjects with pathologically confirmed unresectable locally advanced or metastatic carcinoma which is refractory to standard therapies or for which there is no standard therapy (Part 1 only) * Japanese subjects with pathologically confirmed MET-positive (fulfillin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Rilotumumab is an investigational oncology drug being studied for use in advanced solid tumors. It was evaluated in a Phase 1 clinical trial that included a part for advanced solid tumors and a part for advanced or metastatic gastric or gastroesophageal junction cancer. The drug is still in clinical development.
Rilotumumab is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. Amgen sponsored the clinical trial of Rilotumumab in Japanese subjects with advanced solid tumors or advanced or metastatic gastric or gastroesophageal junction cancer.
Rilotumumab is in Phase 1 clinical development. A Phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or advanced or metastatic gastric or gastroesophageal junction cancer has been completed. The drug is investigational and has not been approved for any use.
Rilotumumab has been studied in one completed clinical trial, identified as NCT01791374. This was a Phase 1/1b study in Japanese subjects with advanced solid tumors or advanced or metastatic gastric or gastroesophageal junction cancer. The trial enrolled 21 participants and was conducted in Japan.
Yes, Rilotumumab is a small molecule drug. It is being developed as an oncology treatment and was studied in a controlled Phase 1 clinical trial. The trial was not randomized or double-blind, and it enrolled adult participants aged 20 years and older.